Compare Aurora Cannabis Inc (ACB) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

SPYI trades at $53.45, up 0.74% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF has surpassed $10 billion in assets under management, driven by strong demand for its covered-call strategy that delivers an 11.86% yield. Recent dividends of $0.52-$0.54 per share highlight its income focus, though key valuation ratios like P/E and P/B are not applicable for this ETF structure.

Outlook remains positive due to robust investor inflows and competitive yield advantages over peers like JEPI. Risks include high fees impacting long-term returns and potential volatility from its options strategy. The fund's tax-efficient distributions appeal to retirees, but reliance on return of capital requires careful monitoring.